Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ranibizumab

ranibizumab

15 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ranibizumab

90 trials tracked of ranibizumab: 49 in phase 3 or 4 and 12 with published results. The most-cited published study has 440 citations.

90Trials tracked
49Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 15 Phase 3 34 Phase 2 34 Phase 1 6 Other / NA 1
  1. Phase 3 RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity Completed · 440 cited
  2. Phase 4 Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) Completed · 302 cited
  3. Phase 3 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed · 114 cited
  4. Phase 4 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) Completed · 99 cited
  5. Phase 3 Rainbow Extension Study Completed · 96 cited
  6. Phase 4 Study EvAluating Genotypes While Using Lucentis 2 Completed · 39 cited
Show 44 more trials
  1. Phase 4 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed · 28 cited
  2. Phase 4 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed · 20 cited
  3. Phase 3 Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration Completed · 9 cited
  4. Phase 3 Lucentis (Ranibizumab) for Eales' Disease Completed · 6 cited
  5. Phase 3 A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS) Completed · 4 cited
  6. Phase 3 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Completed · 1 cited
  7. Phase 4 Head to Head Study of Anti-VEGF Treatment. Completed
  8. Phase 4 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed
  9. Phase 4 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed
  10. Phase 4 Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed
  11. Phase 4 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Completed
  12. Phase 4 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed
  13. Phase 4 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed
  14. Phase 4 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed
  15. Phase 4 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed
  16. Phase 4 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed
  17. Phase 3 To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema Completed
  18. Phase 3 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Completed
  19. Phase 3 Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye Completed
  20. Phase 3 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed
  21. Phase 3 A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration Completed
  22. Phase 3 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration Completed
  23. Phase 3 Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration Completed
  24. Phase 3 Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD Completed
  25. Phase 3 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Completed
  26. Phase 3 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Completed
  27. Phase 3 Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) Completed
  28. Phase 3 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed
  29. Phase 3 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Completed
  30. Phase 3 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) Completed
  31. Phase 3 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) Completed
  32. Phase 3 A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study Completed
  33. Phase 3 Lucentis Versus Mitomycin C During Glaucoma Surgery Completed
  34. Phase 3 Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Completed
  35. Phase 3 Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Completed
  36. Phase 3 Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Completed
  37. Phase 3 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed
  38. Phase 3 Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) Completed
  39. Phase 3 SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Completed
  40. Phase 3 Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  41. Phase 3 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Completed
  42. Phase 3 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) Completed
  43. Phase 3 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Completed
  44. Phase 2 Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) Completed

Showing the 50 most-cited and recently-updated of 90 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
Drug Pipeline FDA Approval
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
FDA Apr 2, 2026
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Ophthalmology Meta-analysis
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Apr 2, 2026
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Oncology Meta-analysis
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
Mar 30, 2026